Cite
HARVARD Citation
Ahluwalia, M. et al. (n.d.). RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA. Neuro-oncology. p. vi234. [Online].